Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Research & Studies
Share your love
Halo And Glare? Not A Problem Anymore!
ESCRS Board Member Prof.Dr. Ewa Mrukwa-Kominek told that Acriva Trinova implanted patients do not experience glare and halos and have very sharp visual equity. Halos are bright circles that surround a light source, like headlights. Glare is light that enters…
Improved Vision Through A Supplement
Mexican marigold also known as cempasúchil, or Aztec marigold is a native flower to México and was first used by the Aztecs and is used in the Mexican holiday “Dia de los muertos” or day of the dead. The Aztecs used it…
Mr. Beast Helps 1,000 People See Again
YouTube Star Mr. Beast, also known as Jimmy Donaldson, has made a significant impact on the lives of 1,000 blind individuals by sponsoring cataract surgeries for them. The successful surgeries have allowed these individuals to regain their sight and experience…
Oral Azithromycin vs Doxycycline for MGD
A study published online in JAMA Ophthalmology found that treatment of severe meibomian gland dysfunction (MGD) with three weeks of oral azithromycin is equivalent to six weeks of doxycycline. The study was conducted by Phit Upaphong, M.D., from Chiang Mai…
Bausch + Lomb Launches Ovd in the U.S.
Bausch + Lomb Corporation has recently launched the StableVisc™ cohesive ophthalmic viscosurgical device (OVD) and the TotalVisc™ Viscoelastic System in the United States. These new products offer eye surgeons dual-action protection during cataract surgery, expanding the range of options available.…
Haag-Streit Launches New EyeSuite Software
Haag-Streit has recently launched EyeSuite software version i9.13, which comes with new features for the Anterior Chamber Suite of the Eyestar 900, as well as market-first functionality for the Lenstar Myopia. Furthermore, Haag-Streit has made additional improvements to its existing…
Ocumension Submits NDA for Zerviate in China
Nicox SA announced that its exclusive Chinese partner, Ocumension Therapeutics, has submitted a new drug application (NDA) seeking approval for commercialization of Zerviate (cetirizine ophthalmic solution), 0.24%, in China. The intended use of Zerviate is for the treatment of ocular…
Tepezza Improves Proptosis in Patients With Chronic TED
Horizon Therapeutics has announced positive and statistically significant topline results from its randomized, double-masked, placebo-controlled Phase 4 clinical trial evaluating TEPEZZA for the treatment of adults with chronic thyroid eye disease (TED) and low CAS, a measure of disease activity.…
Ultomiris Poised for EU Approval as NMOSD Treatment
AstraZeneca’s Ultomiris (ravulizumab) has received a recommendation for marketing authorization in the European Union (EU) for the treatment of adult patients who are anti-aquaporin-4 (AQP4) antibody positive (Ab+) and have neuromyelitis optica spectrum disorder (NMOSD). If authorized, Ultomiris would become…
New Fish Oil Supplement May Reverse Vision Loss
According to a recent study, scientists may have found a promising treatment for one of the leading causes of blindness worldwide. The study suggests that a new fish oil supplement could hold the key to preventing vision loss caused by…